Send to

Choose Destination
J Clin Neurosci. 2014 Mar;21(3):421-6. doi: 10.1016/j.jocn.2013.06.008. Epub 2013 Nov 11.

An audit of immunohistochemical marker patterns in meningioma.

Author information

Department of Clinical Neuroscience, Section of Neurosurgery, Karolinska Institute, R3:02 KS, Stockholm S-17176, Sweden.
Department of Clinical Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden.
Department of Neurosurgery, Alfred Hospital, Monash University, Melbourne, VIC, Australia.
Department of Clinical Neuroscience, Section of Neurosurgery, Karolinska Institute, R3:02 KS, Stockholm S-17176, Sweden. Electronic address:


Meningiomas may express a number of potentially growth-promoting receptors including receptors for progesterone, growth hormone and vascular endothelial growth factor (VEGF). These and other receptors are potential targets for chemotherapy. We have prospectively studied a panel of markers as a routine in order to obtain data of individual expression of markers that may provide targets for anti-receptor treatment. One hundred and seventy-five consecutive patients operated on for meningiomas between 2005 and 2008 were prospectively analysed with antibodies against receptors for growth hormone, insulin-like growth factor 1 (IGF-1), androgen receptors, progesterone receptors (PR) and antibodies against CD34, VEGF, Ki-67 and caspase-3. Expression of IGF-1 receptor (IGF-1r), epidermal growth factor receptor (EGFR) E30 and growth hormone receptor (GHr) was conserved across histological grades and found in 88% to 94% of meningiomas. PR were detected in 87%, but expression decreased in aggressive tumours. Angio-markers such as VEGF and CD34 were detected in 69% and 17% of meningiomas, respectively. Androgen receptors and caspase-3 were uncommon. The analyses of a panel were undertaken as a clinical routine in order to assess its feasibility and to provide data that can be utilised in a clinical setting. Three putative therapeutic receptor targets, IGF-1r, GHr and EGFR E30 were expressed in a large majority of tumours and in contrast to PR maintained expression despite increasing pathological grade of meningioma. Our data also suggest that anti-progesterone therapies and anti-angiogenic therapies could be targeted to subsets of meningioma patients who express PR or have CD34-positive tumours.


EGF; IGF; Meningioma; Neurosurgery; Progesterone; VEGF

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center